| Literature DB >> 33631758 |
Vasantham Annadurai1, John W Blackett1, Daniel Freedberg1, Chin Hur1,2, Peter H R Green1, Benjamin Lebwohl1,3.
Abstract
INTRODUCTION: The COVID-19 pandemic drastically changed hospital workflows. This study aimed to characterize differences in gastrointestinal endoscopies in the New York metropolitan region before, during, and after the first wave of the pandemic.Entities:
Keywords: Coronavirus disease 2019; Endoscopy; Procedure yield; Racial disparities
Mesh:
Year: 2021 PMID: 33631758 PMCID: PMC8089412 DOI: 10.1159/000515431
Source DB: PubMed Journal: Dig Dis ISSN: 0257-2753 Impact factor: 3.421
Baseline characteristics of patients undergoing procedures in the prepandemic and pandemic periods
| Demographics | Prepandemic 16 Mar-17 May (2017-2019) | Pandemic period 16 Mar 2020 17 May 2020 | |
|---|---|---|---|
| Inpatient | |||
| Patients, | 1,181 | 146 | |
| Procedures, | 1,662 | 192 | |
| Mean age, years | 63.4 | 63.7 | 0.80 |
| % female | 45.8 | 41.7 | 0.22 |
| Race, | |||
| American Indian or Alaskan Native | 5 (0.3) | 0 | |
| Asian or Pacific Islander | 70 (4.2) | 7 (3.6) | |
| Black or African American | 395 (23.8) | 46 (24.0) | 0.67 |
| White | 67 (40.7) | 71 (37.0) | |
| Other, unknown, or declined | 515 (31.0) | 68 (35.4) | |
| Ethnicity, | |||
| Hispanic or Latin American | 527 (31.7) | 68 (35.4) | 0.30 |
| Outpatient | |||
| Patients, | 6,346 | 117 | |
| Procedures, | 7,739 | 140 | |
| Mean age, years | 59.2 | 60.1 | 0.46 |
| % female | 57.3 | 47.1 | |
| Race, | |||
| American Indian or Alaskan Native | 11 (0.1) | 0 | |
| Asian | 303 (3.9) | 5 (3.6) | |
| Black or African American | 1,081 (14.0) | 10 (7.1) | |
| White | 4,307 (55.7) | 79 (56.4) | |
| Other, unknown, or declined | 2,026 (26.2) | 46 (32.9) | |
| Ethnicity, | |||
| Hispanic or Latin American | 2,335 (30.2) | 23 (16.4) |
Distribution of common procedures in the prepandemic and pandemic periods
| Procedure type | Prepandemic 16 Mar-17 May (2017-2019) | Pandemic period 16 Mar 2020 17 May 2020 | |
|---|---|---|---|
| Inpatient | |||
| All exams | 1,662 | 192 | |
| EGD | 841 (51) | 95 (49) | 0.77 |
| EUS | 123 (7) | 22 (11) | |
| Alone | 83 (5) | 13 (7) | 0.29 |
| Together with ERCP | 40 (2) | 9 (5) | 0.06 |
| ERCP | 174 (10) | 30 (16) | |
| Colonoscopy | 350 (21) | 28 (14) | |
| Outpatient | |||
| All exams | 7,739 | 140 | |
| EGD | 2,843 (37) | 32 (23) | |
| EUS | 476 (6) | 26 (19) | |
| Alone | 412 (5) | 16 (11) | |
| Together with ERCP | 64 (1) | 10 (7) | |
| ERCP | 291 (4) | 40 (29) | |
| Colonoscopy | 3,765 (49) | 25 (18) |
EGD, esophagogastroduodenoscopy; EUS, endoscopic ultra sound; ERCP, endoscopic retrograde cholangiopancreatography.
Distribution of the most common procedure indications in the prepandemic and pandemic periods
| Procedure indications | Prepandemic 16 Mar-17 May (2017-2019) | Pandemic period 16 Mar 2020 17 May 2020 | |
|---|---|---|---|
| Inpatient | |||
| EGD | 841 | 95 | |
| Bleeding | 483 (57) | 68 (72) | |
| Dysphagia | 87 (10) | 12 (13) | 0.32 |
| Abdominal pain (any location) | 47 (6) | 3 (3) | 0.47 |
| EUS alone | 83 | 13 | |
| Suspected mass or lymphadenopathy | 24 (29) | 5 (38) | 0.52 |
| Cyst or pseudocyst | 15 (18) | 0 (0) | 0.21 |
| EUS with ERCP | 40 | 9 | |
| Suspected mass or lymphadenopathy | 22 (55) | 8 (89) | 0.13 |
| ERCP | 174 | 30 | |
| Bile duct stone | 61 (35) | 8 (27) | 0.37 |
| Jaundice | 40 (23) | 15 (50) | |
| Cholangitis | 17 (10) | 5 (17) | 0.33 |
| Colonoscopy | 350 | 28 | |
| Bleeding | 253 (72) | 22 (79) | 0.47 |
| Abnormal CT of the GI tract | 35 (10) | 5 (18) | 0.20 |
| Screening for colorectal neoplasm | 18 (5) | 0 (0) | 0.38 |
| Outpatient | |||
| EGD | 2,843 | 32 | |
| Heartburn | 524 (18) | 3 (9) | 0.25 |
| Epigastric abdominal pain | 421 (15) | 7 (22) | 0.26 |
| GI bleeding | 240 (8) | 14 (44) | |
| EUS alone | 412 | 15 | |
| Suspected mass or lymphadenopathy | 141 (34) | 13 (87) | |
| Pancreatic cyst or pseudocyst | 70 (17) | 2 (13) | 1 |
| Screening for neoplasm | 37 (9) | 0 (0) | 0.63 |
| EUS with ERCP | 64 | 10 | |
| Suspected mass or lymphadenopathy | 17 (27) | 6 (60) | 0.06 |
| ERCP | 291 | 40 | |
| Stent change or removal | 88 (30) | 4 (10) | |
| Bile duct stone | 47 (16) | 3 (8) | 0.24 |
| Jaundice | 38 (13) | 15 (38) | |
| Colonoscopy | 3,765 | 25 | |
| Screening for neoplasm | 1,629 (43) | 1 (4) | |
| History of polyps (nonmalignant) | 864 (23) | 2 (8) | 0.09 |
| Bleeding | 441 (12) | 9 (36) |
EGD, esophagogastroduodenoscopy; EUS, endoscopic ultrasound; ERCP, endoscopic retrograde cholangiopancreatography; CT, computerized tomography; GI, gastrointestinal.
Diagnostic or therapeutic yield of the most common procedure indications in the prepandemic and pandemic periods
| Procedure and indication | Procedure yield | ||
|---|---|---|---|
| Prepandemic 15 Sep 2019-15 Mar 2020, | pandemic period 16 Mar 2020-17 May 2020, | ||
| EGD for bleeding | 350 | 68 | |
| Positive findings, | 195 (56) | 45 (66) | 0.11 |
| Source not identified, | 155 (44) | 23 (34) | |
| EUS alone for suspected malignancy | 31 | 5 | |
| Positive findings, | 21 (68) | 4 (80) | 1 |
| Pathology positive for malignancy | 21 | 4 | |
| Negative findings, | 10 (32) | 1 (20) | |
| Pathology “atypical” | 2 | 0 | |
| No mass or pathology negative | 8 | 1 | |
| EUS with ERCP for suspected malignancy | 32 | 8 | |
| Positive findings, | 19 (59) | 5 (63) | 1 |
| Pathology positive for malignancy | 17 | 4 | |
| Findings “suspicious“ for malignancy | 2 | 1 | |
| Negative findings, | 13 (41) | 3 (38) | |
| Pathology “atypical” | 1 | 2 | |
| No mass or pathology negative | 12 | 1 | |
| ERCP for jaundice | 61 | 13 | |
| Postprocedure improvement in LFTs, | 39 (64) | 7 (54) | 0.54 |
| No postprocedure improvement in LFTs, | 22 (36) | 6 (46) | |
| Colonoscopy for bleeding | 100 | 22 | |
| Positive findings, | 54 (54) | 12 (55) | 0.96 |
| Source identified | 53 | 12 | |
| Source likely identified | 1 | 0 | |
| Negative findings, | 46 (46) | 10 (45) | |
| Source not identified | 46 | 10 | |
| EGD for GI bleeding | 100 | 14 | |
| Positive findings, | 19 (19) | 8 (57) | |
| Source identified | 19 | 7 | |
| Source likely identified | 0 | 1 | |
| Negative findings, | 81 (81) | 6 (43) | |
| Source not identified | 81 | 6 | |
| EUS alone for suspected malignancy | 100 | 13 | |
| Positive findings, | 41 (41) | 9 (69) | 0.07 |
| Pathology positive for malignancy | 40 | 8 | |
| Findings “suspicious“ for malignancy | 1 | 1 | |
| Negative findings, | 59 (59) | 4 (31) | |
| Pathology “atypical” | 5 | 2 | |
| No mass or pathology negative | 54 | 2 | |
| EUS with ERCP for suspected malignancy | 28 | 6 | |
| Positive findings, | 14 (50) | 5 (83) | 0.20 |
| Pathology positive for malignancy | 13 | 3 | |
| Findings “suspicious“ for malignancy | 1 | 2 | |
| Negative findings, | 14 (50) | 1 (17) | |
| Pathology “atypical” | 4 | 1 | |
| No mass or pathology negative | 10 | 0 | |
| ERCP for jaundice | 17 | 10 | |
| Positive findings, | 13 (76) | 7 (70) | 1 |
| Improvement in LFTs | 9 | 7 | |
| ye Possible improvement in LFTs | 4 | 0 | |
| Negative findings, n (%) | 4 (24) | 3 (30) | |
| No improvement in LFTs | 4 | 3 | |
| Colonoscopy for bleeding | 100 | 9 | |
| Positive findings, | 71 (71) | 9 (100) | 0.11 |
| Source identified | 12 | 5 | |
| Source possibly identified | 59 | 4 | |
| Negative findings, | 29 (29) | 0 (0) | |
| Source not identified | 29 | 0 | |
EGD, esophagogastroduodenoscopy; EUS, endoscopic ultrasound; ERCP, endoscopic retrograde cholangiopancreatography; LFT, liver function test.
Procedure yield is defined as the following: for upper GI endoscopies for bleeding: whether a source of bleed was identified. For EUS alone for suspected malignancy: whether pathology or cytology from a biopsy during EUS resulted positive or was classified as “suspicious” for malignancy. For EUS with ERCP for suspected malignancy: whether pathology or cytology from a biopsy either during EUS or during ERCP resulted positive or was classified as “suspicious” for malignancy. For ERCP for jaundice: whether LFTs improved within 72 h of procedure for inpatient procedures, or in the next set of bloodwork drawn within 2 months for outpatient procedures. Some cases were classified as “possible improvement” if LFTs were already declining prior to the procedure and continued to decline after. For colonoscopy for bleeding: whether a source of bleed was identified. ‘For each procedure indication, if >100 completed procedures existed, a random sample of 100 procedures were chosen for review. Inpatient EGDs were reviewed in further detail, with a random sample of 350 procedures chosen for review. Some ERCPs were not applicable for review due to a lack of follow-up bloodwork.